EE200300501A - Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid - Google Patents

Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid

Info

Publication number
EE200300501A
EE200300501A EEP200300501A EEP200300501A EE200300501A EE 200300501 A EE200300501 A EE 200300501A EE P200300501 A EEP200300501 A EE P200300501A EE P200300501 A EEP200300501 A EE P200300501A EE 200300501 A EE200300501 A EE 200300501A
Authority
EE
Estonia
Prior art keywords
imidazotriazinone
formulations
nasal administration
nasal
administration
Prior art date
Application number
EEP200300501A
Other languages
English (en)
Estonian (et)
Inventor
Serno Peter
Ohm Andreas
Barth Wolfgang
Bauer Richard-Josef
Siefert Hans-Martin
Zimmer Dieter
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE200300501A publication Critical patent/EE200300501A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300501A 2001-04-12 2002-04-03 Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid EE200300501A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10118306A DE10118306A1 (de) 2001-04-12 2001-04-12 Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
PCT/EP2002/003663 WO2002083674A2 (de) 2001-04-12 2002-04-03 Imidazotriazinonhaltige zusammensetzungen zur nasalen applikation

Publications (1)

Publication Number Publication Date
EE200300501A true EE200300501A (et) 2003-12-15

Family

ID=7681379

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300501A EE200300501A (et) 2001-04-12 2002-04-03 Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid

Country Status (25)

Country Link
US (2) US6740306B2 (de)
EP (1) EP1381368A2 (de)
JP (1) JP2004525968A (de)
KR (1) KR20030087072A (de)
CN (1) CN1537004A (de)
AR (1) AR035821A1 (de)
BG (1) BG108245A (de)
BR (1) BR0208813A (de)
CA (1) CA2443639A1 (de)
CZ (1) CZ20032752A3 (de)
DE (1) DE10118306A1 (de)
DO (1) DOP2002000373A (de)
EC (1) ECSP034795A (de)
EE (1) EE200300501A (de)
GT (1) GT200200070A (de)
HU (1) HUP0303877A3 (de)
IL (1) IL158255A0 (de)
MX (1) MXPA03009314A (de)
NO (1) NO20034556L (de)
PE (1) PE20021035A1 (de)
PL (1) PL363033A1 (de)
RU (1) RU2003133143A (de)
SK (1) SK12682003A3 (de)
UY (1) UY27256A1 (de)
WO (1) WO2002083674A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
ZA200704869B (en) * 2004-12-23 2009-02-25 Roxro Pharma Inc Therapeutic compositions for intranasal administration of ketorolac
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
US20100184769A1 (en) * 2007-06-13 2010-07-22 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
MX2010013484A (es) * 2008-06-13 2011-03-29 Roxro Pharma Inc Star Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
US8551454B2 (en) * 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8277781B2 (en) * 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2021242913A1 (en) * 2020-05-26 2021-12-02 Strategic Drug Solutions, Inc. Formulations and methods for treating erectile dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602099A (en) * 1973-04-02 1986-07-22 Merrell Dow Pharmaceuticals Inc. Antirhinovirus agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
WO1997045427A1 (fr) 1996-05-31 1997-12-04 Mochida Pharmaceutical Co., Ltd. DERIVES DE PYRIDOCARBAZOLE AYANT UN EFFET INHIBITEUR DE cGMP-PDE
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 勃起机能障碍治疗剂
CA2304112A1 (en) 1997-09-23 1999-04-01 John Harrison Heiligenstein Treatment of attention-deficit/hyperactivity disorder
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
AU4717299A (en) * 1998-06-26 2000-01-17 Nastech Pharmaceutical Company, Inc Nasal delivery of sildenafil citrate
CN1526448A (zh) * 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗肛门直肠病的药物和方法

Also Published As

Publication number Publication date
WO2002083674A2 (de) 2002-10-24
WO2002083674A3 (de) 2003-01-09
SK12682003A3 (sk) 2004-03-02
AR035821A1 (es) 2004-07-14
CN1537004A (zh) 2004-10-13
ECSP034795A (es) 2003-12-01
NO20034556D0 (no) 2003-10-10
CZ20032752A3 (cs) 2004-01-14
PL363033A1 (en) 2004-11-15
HUP0303877A2 (hu) 2004-03-29
RU2003133143A (ru) 2005-04-10
US20030022894A1 (en) 2003-01-30
EP1381368A2 (de) 2004-01-21
DOP2002000373A (es) 2002-11-30
CA2443639A1 (en) 2002-10-24
HUP0303877A3 (en) 2005-05-30
MXPA03009314A (es) 2004-03-10
US6740306B2 (en) 2004-05-25
IL158255A0 (en) 2004-05-12
PE20021035A1 (es) 2002-11-29
NO20034556L (no) 2003-12-10
UY27256A1 (es) 2002-11-29
BR0208813A (pt) 2004-03-09
US20040248891A1 (en) 2004-12-09
DE10118306A1 (de) 2002-10-17
GT200200070A (es) 2003-01-31
BG108245A (en) 2005-01-31
JP2004525968A (ja) 2004-08-26
KR20030087072A (ko) 2003-11-12

Similar Documents

Publication Publication Date Title
NO20033556L (no) Farmasöytiske formuleringer
DK1399127T3 (da) Olopatadinformuleringer til topisk administration
EE05581B1 (et) Aripiprasooli ravimlahus peroraalseks manustamiseks
NO20033384L (no) Farmasoytisk formulering
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
CY2014019I1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
NO20033785D0 (no) Farmasöytisk formulering
CY2013011I2 (el) Μεθοδος χορηγησης διφωσφονικων
PT1501534E (pt) Formulacoes farmaceuticas
FI20011478A0 (fi) Farmaseuttinen koostumus
DK1414409T3 (da) Stabiliseret oral suspensionsformulering
NO20040125L (no) Enterale formuleringer
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
NO20035627D0 (no) Farmasöytisk formulering
IS7051A (is) Lyfjasamsetningar
NO20040047L (no) Farmasoytisk formulering for intramuskulaer administrering av fulvestrant
FI20022128A (fi) Farmaseuttinen koostumus
HK1064953A1 (en) Compositions for nasal administration of insulin
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
NO20041236L (no) Farmasoytisk formulering
DK1330280T3 (da) Lægemiddelinhalator